SCHEMBL334107

SCHEMBL334107

COc1ccc(C(CC2CO2)O[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.37
APLNR P35414 1/20 0.36
KMT2A Q03164 4/20 0.35
TSHR P16473 3/20 0.35
MEN1 O00255 3/20 0.35
TP53 P04637 2/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 2/20 0.35
AOC3 Q16853 1/20 0.35
PPARG P37231 1/20 0.35
HIF1A Q16665 1/20 0.35
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334612 0.85 KMT2A (0.38) KMT2ATSHRMEN1TP53MAPT
SCHEMBL9826255 0.81 PKM (0.43) PKMKMT2ATSHRMEN1TP53
SCHEMBL9567005 0.76 AOC3 (0.39) APLNRTSHRMAPTALDH1A1CYP1A2
SCHEMBL9567003 0.76 AOC3 (0.39) APLNRTSHRMAPTALDH1A1CYP1A2
SCHEMBL9181120 0.74 ADRB2 (0.39) PKMAPLNRTSHRALDH1A1AOC3
SCHEMBL9181124 0.74 ADRB2 (0.39) PKMAPLNRTSHRALDH1A1AOC3
SCHEMBL15614009 0.70 ALDH1A1 (0.55) PKMAPLNRKMT2ATSHRMEN1
SCHEMBL16900479 0.69 NPSR1 (0.39) PKMAPLNRKMT2AMEN1HPGD
SCHEMBL2292972 0.68 ALDH1A1 (0.36) TSHRALDH1A1MAPK1
SCHEMBL2287051 0.68 ALDH1A1 (0.36) TSHRALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PKM 4614/4885APLNR 3669/4885KMT2A 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.